An Open Label Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Nimodipine (Primary)
- Indications Dementia
- Focus Adverse reactions
- 16 May 2016 Biomarkers information updated
- 10 Dec 2013 Planned End Date changed from 1 Apr 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 30 Apr 2013 New trial record